A study by researchers from the International Agency for Research on Cancer, published in JAMA Oncology, demonstrates that a blood test measuring four protein biomarkers can improve the identification of individuals who would later develop lung cancer.
Genentech, a member of the Roche Group, announced that phase III IMpassion130 study met its co-primary endpoint of progression free survival.
According to data presented by NewLink, all 10 newly diagnosed DIPG patients in a phase I study demonstrated initial symptomatic improvement after treatment with indoximod and chemotherapy.
AstraZeneca and Merck announced positive results from the randomized, double-blind, placebo-controlled, phase III SOLO-1 trial of Lynparza (olaparib) tablets.
Genentech said that the phase III IMpower133 study met its co-primary endpoints of overall survival and progression-free survival at its first interim analysis.
Taiho Oncology Inc. and Servier announced clinical data from the pivotal phase III trial (TAGS) evaluating LONSURF (trifluridine and tipiracil, TAS-102) plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated metastatic gastric cancer refractory to standard therapies.
To ensure the well-being and safety of healthcare providers and patients, the Oncology Nursing Society developed the Toolkit for Safe Handling of Hazardous Drugs for Nurses in Oncology.
Novartis announced 14-month results from the pivotal JULIET clinical trial showing ongoing durable responses are achievable with Kymriah (tisagenlecleucel) when administered to adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Taiho Oncology Inc. and Servier announced clinical data from the pivotal phase III trial (TAGS) evaluating Lonsurf (trifluridine and tipiracil, TAS-102) plus best supportive care versus placebo plus BSC in patients with previously treated metastatic gastric cancer refractory to standard therapies.
Higher levels of vitamin D are associated with decreasing risk of breast cancer, according to researchers at University of California San Diego School of Medicine who conducted an epidemiological study published in the June 15 online issue of PLOS ONE.
